Indication Sought for Breakthrough Pain Associated with Chronic Pain
Conditions in Patients Who are Already Taking Opioid Medications
FRAZER, Pa., Nov. 12 /PRNewswire-FirstCall/ -- Cephalon, Inc. (Nasdaq: CEPH) today announced it has submitted a supplemental New Drug Application (sNDA) to the U.S. Food and Drug Administration (FDA) seeking approval to market FENTORA(R) (fentanyl buccal tablet) [C-II] for the management of breakthrough pain in opioid tolerant patients with chronic pain conditions. Breakthrough pain is characterized by its rapid onset, moderate- to-severe intensity, and relatively short duration. According to a study published in the August 2006 issue of The Journal of Pain, up to 74 percent of patients with non-cancer chronic pain conditions treated for persistent pain, such as chronic low back and chronic neuropathic pain, will experience breakthrough pain. Currently FENTORA is approved for the management of breakthrough pain in patients with cancer who are already receiving and who are tolerant to opioid therapy for their underlying persistent pain.
"The clinical trials supporting this submission mark the first time a pain medication has been evaluated as a treatment for breakthrough pain associated with serious chronic pain conditions other than cancer," said Dr. Lesley Russell, Executive Vice President, Worldwide Medical and Regulatory Operations. "We look forward to working with FDA to broaden the use of FENTORA to opioid tolerant patients with unresolved debilitating breakthrough pain."
The FENTORA sNDA includes data from three randomized,
placebo-controlled clinical trials and one long-term open-label safety
study with a total of 941 opioid tolerant patients. The patients in the
FENTORA sNDA trials were treated for up to 18 months and had a broad range
of underlying chronic pain conditions, including chronic low back and
chronic neuropathic pain. In the randomiz
|SOURCE Cephalon, Inc.|
Copyright©2007 PR Newswire.
All rights reserved